TENX TENAX THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 34956 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY0.4%
TTM EPS YoY-87.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.2%
ROA-59.8%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets7.1%
Debt / equity0.00x
Current ratio14.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| R&D expense | $12.07M | $12.85M | $11.54M | $10.54M | $10.33M | $6.12M | $5.68M | $4.59M |
| SG&A expense | $5.66M | $5.93M | $5.03M | $5.91M | $6.48M | $5.67M | $5.66M | $2.70M |
| Operating income | -$17.73M | -$18.78M | -$16.57M | -$16.45M | -$16.81M | -$11.79M | -$11.34M | -$31.69M |
| Interest expense | — | — | — | $0 | $0 | $0 | $0 | -$465 |
| Net income | -$16.70M | -$17.80M | -$15.72M | -$15.54M | -$15.80M | -$10.85M | -$10.41M | -$28.94M |
| EBITDA | — | — | — | — | — | — | — | -$31.69M |
| EPS (basic) | -0.31 | -0.35 | -0.35 | — | -0.40 | -0.27 | -0.28 | — |
| EPS (diluted) | -0.31 | -0.35 | -0.35 | — | -0.40 | -0.27 | -0.28 | — |
| Weighted avg. shares (diluted) | 53.45M | 50.87M | 45.23M | — | 39.74M | 39.57M | 36.58M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $113.70M | $118.00M | $118.80M | $97.56M | $99.37M | $105.46M | $111.45M | $94.85M |
| Current assets | $117.01M | $121.66M | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M |
| Total assets | $117.01M | $121.66M | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M |
| Current liabilities | $8.36M | $8.07M | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M |
| Total liabilities | $8.36M | $8.07M | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M |
| Shareholders' equity | $108.66M | $113.59M | $114.69M | $97.07M | $96.21M | $103.33M | $109.29M | $91.99M |
| Shares outstanding | 45.54M | 31.95M | 24.28M | 9.31M | 5.91M | 4.15M | 3.97M | 3.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.48M | -$14.15M | -$9.31M | -$13.41M | -$9.15M | -$6.26M | -$6.97M | -$3.53M |
| Investing cash flow | — | — | — | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $8.23M | $13.37M | $30.50M | $11.61M | $3.06M | $278,000 | $23.56M | $67,245 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | $2.40M | $2.80M | $2.84M | $4.79M | $5.50M | $4.50M | $4.14M | $970,000 |
Free plan shows the latest 8 periods; Pro shows all 68 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.